-
Posted by
Two Blokes Jul 2 -
Filed in
Stock
-
3 views
NanoViricides (NYSE-A:NNVC) announced it is moving forward with Phase 2 clinical development of its experimental antiviral therapy, NV-387, for the treatment of Mpox. The company has selected Mpox as the first indication among several viral targets studied in preclinical models, including RSV, influenza, and COVID-19.
